Defence Therapeutics - Stock

Defence Therapeutics Liabilities 2024

Defence Therapeutics Liabilities

1.97 M CAD

Ticker

DTC.CN

ISIN

CA24463V1013

WKN

A3CN14

In 2024, Defence Therapeutics's total liabilities amounted to 1.97 M CAD, a 77.61% difference from the 1.11 M CAD total liabilities in the previous year.

Defence Therapeutics Aktienanalyse

What does Defence Therapeutics do?

Defence Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Defence Therapeutics's Liabilities

Defence Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Defence Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Defence Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Defence Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Defence Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Defence Therapeutics Stock

What is the level of liabilities of Defence Therapeutics this year?

Defence Therapeutics has a debt balance of 1.97 M CAD this year.

What were the liabilities of Defence Therapeutics compared to the previous year?

The liabilities of Defence Therapeutics have increased by 77.61% increased compared to the previous year.

What are the consequences of high debt for investors of Defence Therapeutics?

High liabilities can pose a risk for investors of Defence Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Defence Therapeutics?

Low liabilities mean that Defence Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Defence Therapeutics affect the company?

An increase in liabilities of Defence Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Defence Therapeutics affect the company?

A decrease in the liabilities of Defence Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Defence Therapeutics?

Some factors that can influence the liabilities of Defence Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Defence Therapeutics so important for investors?

The liabilities of Defence Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Defence Therapeutics take to modify the liabilities?

To change its liabilities, Defence Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Defence Therapeutics pay?

Over the past 12 months, Defence Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Defence Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Defence Therapeutics?

The current dividend yield of Defence Therapeutics is .

When does Defence Therapeutics pay dividends?

Defence Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Defence Therapeutics?

Defence Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Defence Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Defence Therapeutics located?

Defence Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Defence Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Defence Therapeutics from 6/17/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Defence Therapeutics pay the last dividend?

The last dividend was paid out on 6/17/2024.

What was the dividend of Defence Therapeutics in the year 2023?

In the year 2023, Defence Therapeutics distributed 0 CAD as dividends.

In which currency does Defence Therapeutics pay out the dividend?

The dividends of Defence Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Defence Therapeutics

Our stock analysis for Defence Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Defence Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.